Powered by Google Google ÜbersetzerGoogle Übersetzer
Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Latest Press Releases
View all
TimeHeadline
6h agoDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
7h agoRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
9h agoThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
16h agoBuffalo Potash Files Annual Information Form and New Technical Report
17h agoIonik Announces 30-Day Extension of Senior Debt Facility
Bioversys Ag logo

Bioversys Ag

About

27.00CHF-0.30 -1.10%
Closed • Updated at 20:09 GMT+00:00
Market Cap$200.70M
Volume2.3K
Beta-0.60
RSI47.41
Health TechnologyBiotechnology

Bioversys Ag — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 16 2026
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
Apr 15 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
Apr 13 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
Mar 31 2026
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
Mar 18 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025

Community Chat

Ask AI

Try asking
6ix6ixAIEvents